A group of scientists at University of Montreal, The Neuro and ŗ«¹śĀćĪč has been awarded a major research grant of over $12.5 million from the Aligning Science Across Parkinsonās (ASAP) initiative over the next three years to study Parkinsonās disease. ASAPās implementation partner The Michael J Fox Foundation for Parkinsonās Research issued the grant.
Parkinsonās disease, the second most prevalent neurodegenerative disease, affects a growing number of people within an aging population. While Parkinsonās disease can be treated, there is currently no cure. This award to the Montreal team is one of the twenty-one new grants awarded by ASAP to Parkinsonās disease experts throughout the world. By awarding more than US$161 million to basic science research in Parkinsonās disease in this first round of financing, ASAP is creating a unique virtual institute where open science and active collaboration across the world will synergise the fight against Parkinsonās disease.
This interdisciplinary group from Montreal will be investigating a new aspect of Parkinsonās disease centered around their breakthrough discovery of the contribution of autoimmune mechanisms in the disease. āOur recent work unravelled some of the mechanisms that link the mutations found in Parkinsonās disease patients to critical roles in the immune system. This finding opened up new avenues to understand the disease process and develop novel immune-based therapeutic approaches,ā said Michel Desjardins, the lead investigator of the project from University of Montreal. āThis unprecedented level of funding will allow our team to take a holistic approach in studying Parkinsonās disease from multiple fronts including work in isolated cells, in mouse models of the disease, and in samples from Parkinsonās patients,ā added Heidi McBride, a cell biologist at The Neuro.
āIn our mouse model carrying a mutation in a gene related to Parkinsonās disease, a simple gut infection was sufficient to initiate the disease process. This new funding will allow us to unravel the molecular, cellular and systemic processes defining a gut-brain axis in the disease,ā explained Samantha Gruenheid, a microbiologist at ŗ«¹śĀćĪč.
Jo Anne Stratton, a neuroimmunologist at The Neuro and expert in the use of single cell sequencing, will use this powerful approach to generate a high-resolution map of the cell changes in complex biological processes over time, and translate these findings into human models derived from patient cells. āOver the last few years, we have been working hard to understand how infections and events in the gut can lead to the destruction of dopaminergic neurons in the brain, a hallmark of the disease responsible for the motor impairments associated with Parkinson. We will explore whether an attack of the peripheral and central nervous system by the immune system might explain many of the patientās symptoms observed years before the emergence of motor impairments,ā said Louis-Eric Trudeau, a neuroscientist and Parkinsonās disease expert at University of Montreal.